The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Associate Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.
Get full access to this article
View all access options for this article.
References
1.
BurrisHA3rd, HurwitzH.L., DeesE.C.. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol.2005; 23: 5305–5313.
GomezH.L., ChavezM.A., DovalD.C.. Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer [abstract 1071]. 28th Annual San Antonio Breast Cancer Symposium 2005. Available at: www.sabcs.org. Accessed February 20, 2006.
BurrisH.A., StornioloA.M., OvermoyerE.A.. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab [abstract 3043]. 29th Annual San Antonio Breast Cancer Symposium 2006. Available at: www.sabcs.org. Accessed February 20, 2006.
ChuQ., CianfroccaM.E., MurrayN.. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients [abstract 6044]. 29th Annual San Antonio Breast Cancer Symposium 2006. Available at: www.sabcs.org. Accessed March 23, 2007.
13.
GeyerC.E., ForsterJ., LindquistD.. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med.2006; 355: 2733–2743.
KellyW.K., O'ConnorO.A., KrugL.M.. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol.2005; 23: 3923–3931.
21.
O'ConnorO.A., HeaneyM.L., SchwartzL.. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol.2006; 24: 166–173.
Garcia-ManeroG., YangH., Sanchez-GonzalezB.. Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome [abstract 2801]. Proc Am Soc Hematol.2005. Available at: www.hematology.org. Accessed March 23, 2007.
LuuT., MorganR.J., LeongL.. Vorinostat (suberoylanilide hydroxamic acid -SAHA) as salvage therapy in metastatic breast cancer (BC): a California cancer consortium phase II study [abstract 1109]. 29th Annual San Antonio Breast Cancer Symposium 2006. Available at: www.sabcs.org. Accessed March 23, 2007.
